Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Candel Therapeutics, Inc.CADL · Entity 4969 | Director | June 23, 2026 | June 24, 2026 |
| OPKO HEALTH, INC.OPK · Entity 4891 | Director · Chief Innovation Officer | May 27, 2025 | May 29, 2025 |
| SIGA TECHNOLOGIES INCSIGA · Entity 6205 | Director | June 09, 2026 | June 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Candel Therapeutics, Inc.
Report date June 23, 2026 · Filed June 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.08 · Expires 2036-06-23 | Direct | 32,000 |
Reported balance
After 2026-06-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-23 · Grant · Acquired 32,000 · Balance 32,000 F1: This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 23, 2027 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting. |
Filing footnotes · ownership attribution and instrument terms
F1: This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 23, 2027 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting.
OPKO HEALTH, INC.
Report date May 27, 2025 · Filed May 29, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.31 · Expires 2035-05-26 | Direct | 437,500 |
Reported balance
After 2025-05-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-05-27 · Grant · Acquired 437,500 · Balance 437,500 F1: This option will vest in four equal annual installments beginning May 27, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: This option will vest in four equal annual installments beginning May 27, 2026.
SIGA TECHNOLOGIES INC
Report date June 09, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $.0001 per shareSEC Table I · non-derivative | Direct | 73,754 |
Ending reported balance
After 2026-06-09 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-09 · Exercise / conversion · Acquired 24,116 · Balance 80,989 F1: Restricted stock units ("RSUs") represent contingent rights to receive common stock of SIGA Technologies, Inc. (the "Company") on a one-for-one basis. Row 2 · 2026-06-09 · Disposition to issuer · Disposed 7,235 · Balance 73,754 F2: Reflects RSUs that were cash-settled, per the terms of the compensation program for Board Directors and as noted on the Form 4 filed on June 11, 2025. Partial cash-settlement of RSUs under the Board compensation program is designed to address tax obligations in connection with the vesting of RSUs. |
| Restricted Stock UnitesSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-09 · Exercise / conversion · Disposed 24,116 · Balance 0 F1: Restricted stock units ("RSUs") represent contingent rights to receive common stock of SIGA Technologies, Inc. (the "Company") on a one-for-one basis. F3: The RSUs were granted on June 10, 2025, and fully vested on the date of the Company's 2026 annual meeting of stockholders. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 34,169 |
Reported balance
After 2026-06-09 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-09 · Grant · Acquired 34,169 · Balance 34,169 F4: RSUs represent contingent rights to receive common stock of the Company on a one-for-one basis, of which up to 10,251 RSUs are expected to settle in cash value thereof but may be settled in shares at the discretion of the Board of Directors. F5: The RSUs fully vest on the date of the Company's 2027 annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units ("RSUs") represent contingent rights to receive common stock of SIGA Technologies, Inc. (the "Company") on a one-for-one basis.
F2: Reflects RSUs that were cash-settled, per the terms of the compensation program for Board Directors and as noted on the Form 4 filed on June 11, 2025. Partial cash-settlement of RSUs under the Board compensation program is designed to address tax obligations in connection with the vesting of RSUs.
F3: The RSUs were granted on June 10, 2025, and fully vested on the date of the Company's 2026 annual meeting of stockholders.
F4: RSUs represent contingent rights to receive common stock of the Company on a one-for-one basis, of which up to 10,251 RSUs are expected to settle in cash value thereof but may be settled in shares at the discretion of the Board of Directors.
F5: The RSUs fully vest on the date of the Company's 2027 annual meeting of stockholders.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 14, 2022 Filed Jun 16, 2022 21:47 UTC | SIGA TECHNOLOGIES INC SIGA · Entity 6205 | Exercise / conversionRestricted Stock Units · Derivative | 22,831 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-037562 · doc4.xml · derivative · entry 3 Nabel Gary J. · CIK 0001867450 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $.0001 per share · 22,831 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units ("RSUs") represent contingent rights to receive common stock of SIGA Technologies, Inc. (the "Company") on a one-for-one basis. F3 · derivative.exercise_date: The RSUs were granted on June 15, 2021, and fully vested on the date of the Company's 2022 annual meeting of stockholders. F3 · derivative.expiration_date: The RSUs were granted on June 15, 2021, and fully vested on the date of the Company's 2022 annual meeting of stockholders. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 21:47 UTC | SIGA TECHNOLOGIES INC SIGA · Entity 6205 | Disposition to issuerCommon Stock, par value $.0001 per share | 6,849 | $10.26 | $70,270.74 |
DisclosureSEC source: 0001209191-22-037562 · doc4.xml · nonDerivative · entry 2 Nabel Gary J. · CIK 0001867450 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,982 F2 · kind: Reflects RSUs that were cash-settled, per the terms of the compensation program for Board Directors and as noted on the Form 4 filed on June 17, 2021. Partial cash-settlement of RSUs under the Board compensation program is designed to address tax obligations in connection with the vesting of RSUs. F2 · acquired: Reflects RSUs that were cash-settled, per the terms of the compensation program for Board Directors and as noted on the Form 4 filed on June 17, 2021. Partial cash-settlement of RSUs under the Board compensation program is designed to address tax obligations in connection with the vesting of RSUs. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 21:47 UTC | SIGA TECHNOLOGIES INC SIGA · Entity 6205 | Exercise / conversionCommon Stock, par value $.0001 per share | 22,831 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-037562 · doc4.xml · nonDerivative · entry 1 Nabel Gary J. · CIK 0001867450 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,831 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units ("RSUs") represent contingent rights to receive common stock of SIGA Technologies, Inc. (the "Company") on a one-for-one basis. Read SEC document |
| May 18, 2022 Filed May 19, 2022 20:28 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | PurchaseCommon Stock | 68,492 | $2.90 | $198,626.80 |
DisclosureSEC source: 0001209191-22-030517 · doc4.xml · nonDerivative · entry 2 Nabel Gary J. · CIK 0001867450 · Director · Chief Innovation Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,471 Read SEC document |
| May 12, 2022 Filed May 19, 2022 20:28 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | PurchaseCommon Stock | 6,979 | $2.65 | $18,494.35 |
DisclosureSEC source: 0001209191-22-030517 · doc4.xml · nonDerivative · entry 1 Nabel Gary J. · CIK 0001867450 · Director · Chief Innovation Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,979 Read SEC document |
| May 09, 2022 Filed May 12, 2022 01:44 UTC | OPKO HEALTH, INC. OPK · Entity 4891 | GrantStock Option (Right to Buy) · Derivative | 34,923 | $0.00 Strike: $3.20 | $0.00 |
DisclosureSEC source: 0001209191-22-028435 · doc4.xml · derivative · entry 1 Nabel Gary J. · CIK 0001867450 · Director · Chief Innovation Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,923 Underlying: Common Stock · 34,923 shares Expires 2032-05-08 F1 · derivative.exercise_date: This option will vest in four equal annual installments beginning May 9, 2023. Read SEC document |
| May 09, 2022 Filed Jun 22, 2022 20:45 UTC Amendment | OPKO HEALTH, INC. OPK · Entity 4891 | GrantCommon Stock | 19,777,514 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-038694 · doc4a.xml · nonDerivative · entry 2 Nabel Gary J. · CIK 0001867450 · Director · Chief Innovation Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the EGN 2021 TRUST Disclosed balance after: 19,777,514 F1 · date: This Form 4 amendment is being filed to report the acquisition of shares of the Issuer's common stock by the GJN 2021 TRUST and the EGN 2021 TRUST, in each case, pursuant to the ModeX Merger (as defined below), inadvertently omitted in the original Form 4. F4 · price: Received in exchange for 2,250,000 shares of ModeX held directly by the EGN 2021 TRUST in connection with the ModeX Merger. F5 · ownership.nature: Shares held by the EGN 2021 TRUST for the benefit of the Reporting Person and his descendants, and for which an independent trustee has been appointed. The Reporting Person and the independent trustee serve as investment advisors of the trust. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| May 09, 2022 Filed Jun 22, 2022 20:45 UTC Amendment | OPKO HEALTH, INC. OPK · Entity 4891 | GrantCommon Stock | 19,777,514 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-038694 · doc4a.xml · nonDerivative · entry 1 Nabel Gary J. · CIK 0001867450 · Director · Chief Innovation Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Held by the GJN 2021 TRUST Disclosed balance after: 19,777,514 F1 · date: This Form 4 amendment is being filed to report the acquisition of shares of the Issuer's common stock by the GJN 2021 TRUST and the EGN 2021 TRUST, in each case, pursuant to the ModeX Merger (as defined below), inadvertently omitted in the original Form 4. F2 · price: Received in exchange for 2,250,000 shares of ModeX Therapeutics, Inc., a Delaware corporation ("ModeX"), held directly by the GJN 2021 TRUST in connection with the Agreement and Plan of Merger, dated as of May 9, 2022, by and among the Issuer, ModeX, Orca Acquisition Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Issuer, and Gary J. Nabel, solely in his capacity as sellers' representative, pursuant to which ModeX became a wholly owned subsidiary of the Issuer (the "ModeX Merger"). F3 · ownership.nature: Shares held by the GJN 2021 TRUST for the benefit of the Reporting Person's spouse and descendants, and for which the Reporting Person's spouse serves as co-trustee together with an independent trustee. The Reporting Person's spouse and the independent trustee serve as investment advisors of the trust. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 20:41 UTC | SIGA TECHNOLOGIES INC SIGA · Entity 6205 | GrantRestricted Stock Units · Derivative | 22,831 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-041458 · doc4.xml · derivative · entry 2 Nabel Gary J. · CIK 0001867450 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,831 Underlying: Common Stock, par value $.0001 per share · 22,831 shares Expires not disclosed F2 · derivative.exercise_price: Restricted stock units ("RSUs") represent contingent rights to receive common stock of SIGA Technologies, Inc. (the "Company") on a one-for-one basis, of which up to 6,849 RSUs are expected to settle in cash value thereof but may be settled in shares at the discretion of the board of directors. F3 · derivative.exercise_date: The RSUs fully vest on the date of, and immediately prior to, the Company's 2022 annual meeting of stockholders. F3 · derivative.expiration_date: The RSUs fully vest on the date of, and immediately prior to, the Company's 2022 annual meeting of stockholders. Read SEC document |
| June 15, 2021 Filed Jun 17, 2021 20:41 UTC | SIGA TECHNOLOGIES INC SIGA · Entity 6205 | GrantStock Option (Right to buy) · Derivative | 25,000 | $0.00 Strike: $6.57 | $0.00 |
DisclosureSEC source: 0001209191-21-041458 · doc4.xml · derivative · entry 1 Nabel Gary J. · CIK 0001867450 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock, par value $.0001 per share · 25,000 shares Expires 2031-06-15 F1 · derivative.exercise_date: The options vest immediately upon the grant of such options. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.